🟢 Cybin is trading 5.5% up in pre-market with no clear company-specific catalyst identified

Cybin is trading at $11.13, up +5.50%, with no clear company-specific announcement identified to explain the pre-market rise.

• A Wall Street Zen rating change from “strong sell” to “sell” was reported October 19, but it does not establish a reason for the gain.
• Major U.S. indices were higher in supplied market data, while biotech ETF XBI was reported down 3.65% in pre-market; the move may align with broader-market strength rather than the sector trend.